The TFOS DEWS II Management and Therapy Subcommittee report presents a severity-related management algorithm comprised of four steps. The recommendations represent evidence-based consensus opinion—the report notes that there is a relative lack of Level 1 evidence to support therapeutic recommendations.
“It is also unfortunate that the treatments for DED have not changed drastically since TFOS DEWS,” he said. “There is, however, greater understanding of the pathophysiology of DED and a greater interest, from clinicians, researchers, and patients alike, that has stimulated further research and the development of novel therapies and better ways to diagnose DED.”
The inclusion of an Iatrogenic Dry Eye Subcommittee report is new in DEWS II. By emphasizing the roles played by patients and clinicians in causing DED, it also has implications for management.
“Common iatrogenic causes of DED include cosmetics, contact lens wear and use of topical and systemic medications,” Dr. Nelson said.